Intelligence · Patents
Patents expiring in 2030
Annual patent cliff calendar for 2030 — US pharmaceutical patents by expiration date.
- Patents
- 880
Quick answer
880 indexed pharmaceutical patents have expiration dates in 2030. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 7728148
Acyclic oximyl hepatitis C protease inhibitors
granted -
US 7728004
Crystalline form of a quinolinone-carboxamide compound
granted -
US 7732196
Anti-angiogenic methods and compositions
granted -
US 7732201
Method for production of neuroblasts
granted -
US 7731975
Chimeric filovirus glycoprotein
granted -
US 7732207
Method for expression of small antiviral RNA molecules within a cell
granted -
US 7732445
Myosin light chain kinase inhibitor compounds, compostions and related methods of use
granted -
US 7732441
Azabicycloalkane compounds
granted -
US 7732626
Fused cyclic compounds
granted -
US 7732470
Compositions and methods for the treatment of renal and cardiovascular disease
granted -
US 7732615
N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
granted -
US 7732462
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
granted -
US 7732599
Process for preparing tetrahydrobiopterin and analogs of tetrahydrobiopterin
granted -
US 7731971
Enhanced CTL epitope-containing HIV-1 reverse transcriptase polypeptides
granted -
US 7732475
Histone deacetylase inhibitors
granted -
US 7731953
Methods for use of TSLP and agonists and antagonists thereof
granted -
US 7732446
Dipeptidyl peptidase inhibitors
granted -
US 7731943
Stabilized aqueous aluminum zirconium solutions
granted -
US 7731951
Viruses for the treatment of cellular proliferative disorders
granted -
US 7731685
Coated medical device
granted -
US 7731940
Compositions and methods related to serotonin 5-HT1A receptors
granted -
US 7731939
Vaccine compositions and adjuvant
granted -
US 7732167
Interferon-α/β binding fusion proteins and therapeutic uses thereof
granted -
US 7732576
Tumor suppressor designated TS10Q23.3
granted -
US 7737266
RNAi modulation of SCAP and therapeutics uses thereof
granted -
US 7736646
Methods for modulating angiogenesis with apelin compositions
granted -
US 7736656
Immunogenic compositions and vaccines for Ebola
granted -
US 7737183
β-amyloid and neurofibrillary tangle imaging agents
granted -
US 7737174
Indole inhibitors of MDM2 and the uses thereof
granted -
US 7737265
RNAi modulation of HIF-1 and therapeutic uses thereof
granted -
US 7737118
Rotational intrathecal analgesia
granted -
US 7737177
Processes for preparing crystalline and amorphous mupirocin calcium
granted -
US 7737151
Pyrazine kinase inhibitors
granted -
US 7737282
Benzimidazole compound crystal
granted -
US 7737124
Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
granted -
US 7737256
Antibody against uPA/uPAR
granted -
US 7736652
Antibody fusion proteins: effective adjuvants of protein vaccination
granted -
US 7741365
Peripheral cannabinoid receptor (CB2) selective ligands
granted -
US 7741321
Modulators of ATP-binding cassette transporters
granted -
US 7740867
Method for identification of virulence determinants
granted -
US 7740889
Bacteriocins and novel bacterial strains
granted -
US 7741494
Histone deacetylase inhibitors
granted -
US 7741063
Toxoplasma gondii oocyst protein
granted -
US 7741482
Reference standard for characterization of rosuvastatin
granted -
US 7741091
Methods of producing hyaluronic acid and chimeric and hybrid glycosaminoglycan polymers
granted -
US 7741113
Cell-specific molecule and method for importing DNA into osteoblast nuclei
granted -
US 7741431
Liposomes containing novel targeting and/or fusogenic peptides, preparations containing them and therapeutic use thereof
granted -
US 7741304
Casein kinase 2 antisense therapy
granted
Frequently asked questions
How many pharma patents expire in 2030?
880 published patents in our USPTO index have expiration dates falling in calendar year 2030.